Brain gene therapy with Trojan horse lipid nanoparticles

Corbett, 2020, SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness, Nature, 586, 567, 10.1038/s41586-020-2622-0 Sahin, 2020, COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, Nature, 586, 594, 10.1038/s41586-020-2814-7 Monnard, 1997, Entrapment of nucleic acids in liposomes, Biochim. Biophys. Acta, 1329, 39, 10.1016/S0005-2736(97)00066-7 Wheeler, 1999, Stabilized plasmid–lipid particles: construction and characterization, Gene Ther., 6, 271, 10.1038/sj.gt.3300821 Conniot, 2021, Revisiting gene delivery to the brain: silencing and editing, Biomater. Sci., 9, 1065, 10.1039/D0BM01278E Zhou, 2020, Blood–brain barrier-penetrating siRNA nanomedicine for Alzheimer’s disease therapy, Sci. Adv., 6, 10.1126/sciadv.abc7031 Jiang, 2020, Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes, Sci. Rep., 10, 10.1038/s41598-020-70290-w Arora, 2021, A review of brain-targeted nonviral gene-based therapies for the treatment of Alzheimer’s disease, Mol. Pharm., 18, 4237, 10.1021/acs.molpharmaceut.1c00611 Luo, 2022, Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases, Adv. Sci. (Weinh.), 9 Jagaran, 2022, Lipid nanoparticles: promising treatment approach for Parkinson’s disease, Int. J. Mol. Sci., 23, 9361, 10.3390/ijms23169361 Ediriweera, 2021, Non-viral vector-mediated gene therapy for ALS: challenges and future perspectives, Mol. Pharm., 18, 2142, 10.1021/acs.molpharmaceut.1c00297 Luiz, 2021, Gene therapy based on lipid nanoparticles as non-viral vectors for glioma treatment, Curr. Gene Ther., 21, 452, 10.2174/1566523220999201230205126 Tasset, 2022, Overcoming barriers in non-viral gene delivery for neurological applications, Nanoscale, 14, 3698, 10.1039/D1NR06939J Annu, 2022, Nanoparticle mediated gene therapy: a trailblazer armament to fight CNS disorders, Curr. Med. Chem., 30, 304, 10.2174/0929867329666220105122318 Huwyler, 1996, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. U. S. A., 93, 14164, 10.1073/pnas.93.24.14164 Pardridge, 2003, Gene targeting in vivo with pegylated immunoliposomes, Methods Enzymol., 373, 507, 10.1016/S0076-6879(03)73032-8 Shi, 2001, Brain-specific expression of an exogenous gene after i.v. administration, Proc. Natl. Acad. Sci. U. S. A., 98, 12754, 10.1073/pnas.221450098 Shi, 2001, Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes, Pharm. Res., 18, 1091, 10.1023/A:1010910523202 Zhang, 2003, Global non-viral gene transfer to the primate brain following intravenous administration, Mol. Ther., 7, 11, 10.1016/S1525-0016(02)00018-7 Xia, 2007, Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes, J. Gene Med., 9, 605, 10.1002/jgm.1046 Hou, 2021, Lipid nanoparticles for mRNA delivery, Nat. Rev. Mater., 6, 1078, 10.1038/s41578-021-00358-0 Felgner, 1987, Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. U. S. A., 84, 7413, 10.1073/pnas.84.21.7413 Malone, 1989, Cationic liposome-mediated RNA transfection, Proc. Natl. Acad. Sci. U. S. A., 86, 6077, 10.1073/pnas.86.16.6077 Chonn, 1995, Recent advances in liposomal drug-delivery systems, Curr. Opin. Biotechnol., 6, 698, 10.1016/0958-1669(95)80115-4 Radler, 1997, Structure of DNA–cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes, Science, 275, 810, 10.1126/science.275.5301.810 Koltover, 1998, An inverted hexagonal phase of cationic liposome–DNA complexes related to DNA release and delivery, Science, 281, 78, 10.1126/science.281.5373.78 Finsinger, 2000, Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery, Gene Ther., 7, 1183, 10.1038/sj.gt.3301227 Simberg, 2003, The role of organ vascularization and lipoplex–serum initial contact in intravenous murine lipofection, J. Biol. Chem., 278, 39858, 10.1074/jbc.M302232200 Matsui, 1997, Loss of binding and entry of liposome–DNA complexes decreases transfection efficiency in differentiated airway epithelial cells, J. Biol. Chem., 272, 1117, 10.1074/jbc.272.2.1117 Hong, 1997, Stabilization of cationic liposome–plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery, FEBS Lett., 400, 233, 10.1016/S0014-5793(96)01397-X Barron, 1999, Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes, Gene Ther., 6, 1179, 10.1038/sj.gt.3300929 Allen, 1994, Long-circulating (sterically stabilized) liposomes for targeted drug delivery, Trends Pharmacol. Sci., 15, 215, 10.1016/0165-6147(94)90314-X Monck, 2000, Stabilized plasmid–lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection, J. Drug Target., 7, 439, 10.3109/10611860009102218 Kulkarni, 2018, Lipid nanoparticles enabling gene therapies: from concepts to clinical utility, Nucleic Acid Ther., 28, 146, 10.1089/nat.2018.0721 Jeffs, 2005, A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA, Pharm. Res., 22, 362, 10.1007/s11095-004-1873-z Batzri, 1973, Single bilayer liposomes prepared without sonication, Biochim. Biophys. Acta, 298, 1015, 10.1016/0005-2736(73)90408-2 Stano, 2004, Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method, J. Liposome Res., 14, 87, 10.1081/LPR-120039794 Roy, 1999, Ethanol-induced condensation of calf thymus DNA studied by laser light scattering, J. Phys. Chem. B, 103, 5117, 10.1021/jp983306p Bailey, 2000, Efficient encapsulation of DNA plasmids in small neutral liposomes induced by ethanol and calcium, Biochim. Biophys. Acta, 1468, 239, 10.1016/S0005-2736(00)00264-9 Wang, 2011, Ethanol induces condensation of single DNA molecules, Soft Matter, 7, 4425, 10.1039/c0sm01251c Hassett, 2019, Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines, Mol. Ther. Nucleic Acids, 15, 1, 10.1016/j.omtn.2019.01.013 Carreno, 2022, mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations, Vaccine, 40, 6114, 10.1016/j.vaccine.2022.08.024 Schoenmaker, 2021, mRNA–lipid nanoparticle COVID-19 vaccines: structure and stability, Int. J. Pharm., 601, 10.1016/j.ijpharm.2021.120586 Kulkarni, 2021, The current landscape of nucleic acid therapeutics, Nat. Nanotechnol., 16, 630, 10.1038/s41565-021-00898-0 Mui, 2013, Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles, Mol. Ther. Nucleic Acids, 2, 10.1038/mtna.2013.66 Akinc, 2010, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol. Ther., 18, 1357, 10.1038/mt.2010.85 Tan, 2001, Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity, Mol. Ther., 3, 673, 10.1006/mthe.2001.0311 Yew, 1999, Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes, Hum. Gene Ther., 10, 223, 10.1089/10430349950019011 Ito, 2009, Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice, Eur. J. Pharm. Biopharm., 71, 303, 10.1016/j.ejpb.2008.09.005 Hernandez, 2021, Safety of COVID-19 vaccines administered in the EU: should we be concerned?, Toxicol. Rep., 8, 871, 10.1016/j.toxrep.2021.04.003 Tahtinen, 2022, IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines, Nat. Immunol., 23, 532, 10.1038/s41590-022-01160-y Moghimi, 2022, Pro-inflammatory concerns with lipid nanoparticles, Mol. Ther., 30, 2109, 10.1016/j.ymthe.2022.04.011 Brito, 2014, A cationic nanoemulsion for the delivery of next-generation RNA vaccines, Mol. Ther., 22, 2118, 10.1038/mt.2014.133 Blakney, 2019, Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA, Gene Ther., 26, 363, 10.1038/s41434-019-0095-2 Pardridge, 2022, A historical review of brain drug delivery, Pharmaceutics, 14, 1283, 10.3390/pharmaceutics14061283 Brightman, 1969, Junctions between intimately apposed cell membranes in the vertebrate brain, J. Cell Biol., 40, 648, 10.1083/jcb.40.3.648 Duvernoy, 1983, The vascularization of the human cerebellar cortex, Brain Res. Bull., 11, 419, 10.1016/0361-9230(83)90116-8 Nance, 2012, A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003594 Cornford, 1994, The human brain GLUT1 glucose transporter: ultrastructural localization to the blood–brain barrier endothelia, J. Cereb. Blood Flow Metab., 14, 106, 10.1038/jcbfm.1994.15 Boado, 1998, Up-regulation of blood–brain barrier short-form leptin receptor gene products in rats fed a high fat diet, J. Neurochem., 71, 1761, 10.1046/j.1471-4159.1998.71041761.x Zhang, 2002, Receptor-mediated delivery of an antisense gene to human brain cancer cells, J. Gene Med., 4, 183, 10.1002/jgm.255 Yepuri, 2016, Synthesis of perdeuterated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine ([D82]POPC) and characterisation of its lipid bilayer membrane structure by neutron reflectometry, Chempluschem, 81, 315, 10.1002/cplu.201500452 Podlecki, 1987, Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects, J. Biol. Chem., 262, 3362, 10.1016/S0021-9258(18)61511-X Amaya, 2014, The insulin receptor translocates to the nucleus to regulate cell proliferation in liver, Hepatology, 59, 274, 10.1002/hep.26609 Batista, 2019, The insulin receptor goes nuclear, Cell Res., 29, 509, 10.1038/s41422-019-0185-0 Zhang, 2003, Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer, Mol. Vis., 9, 465 Simunovic, 2009, Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology, Brain, 132, 1795, 10.1093/brain/awn323 Zhang, 2004, Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter, Hum. Gene Ther., 15, 339, 10.1089/104303404322959498 Zhang, 2009, Near complete rescue of experimental Parkinson’s disease with intravenous, non-viral GDNF gene therapy, Pharm. Res., 26, 1059, 10.1007/s11095-008-9815-9 Zhang, 2002, Antisense gene therapy of brain cancer with an artificial virus gene delivery system, Mol. Ther., 6, 67, 10.1006/mthe.2002.0633 Zhang, 2004, Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer, Clin. Cancer Res., 10, 3667, 10.1158/1078-0432.CCR-03-0740 Zhang, 2003, Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes, Pharm. Res., 20, 1779, 10.1023/B:PHAM.0000003375.13655.f9 Uddin, 2021, Challenges of storage and stability of mRNA-based COVID-19 vaccines, Vaccines (Basel), 9, 1033, 10.3390/vaccines9091033 Sun, 2022, Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution, Sci. Data, 9, 67, 10.1038/s41597-022-01167-y Lee, 2020, Lyoprotectant optimization for the freeze-drying of receptor-targeted Trojan horse liposomes for plasmid DNA delivery, Mol. Pharm., 17, 2165, 10.1021/acs.molpharmaceut.0c00310 Mendell, 2017, Single-dose gene-replacement therapy for spinal muscular atrophy, N. Engl. J. Med., 377, 1713, 10.1056/NEJMoa1706198 Ertl, 2022, Immunogenicity and toxicity of AAV gene therapy, Front. Immunol., 13, 10.3389/fimmu.2022.975803 Hudry, 2018, Efficient gene transfer to the central nervous system by single-stranded Anc80L65, Mol. Ther. Methods Clin. Dev., 10, 197, 10.1016/j.omtm.2018.07.006